EUVIMEDEUVIMED entdecken
Crossref

Development and Evaluation of Lumefantrine Nanosuspension for Enhanced Antimalarial Efficacy and Bioavailability

Kirti Naik, Vineeta Khanvilkar, Udaykumar Patil, Aditya Ghuge, Vaishali Jadhav, K.K. Singh, Mugdha Rane

International Journal of Drug Delivery Technology · 11.06.2026 · 16 (52s)

DOI: 10.25258/ijddt.16.52s.91 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 11.06.2026. Verfasst von Kirti Naik und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The goal of the study was to develop, characterize and evaluate lumefantrine nanosuspension (L NS) using combined dry-milling and wet-milling to enhance dissolution, antiplasmodial potency and oral bioavailability compared with conventional lumefantrine suspension (L S) for improved malaria treatment. Materials and Methods: Nanosuspensions were prepared by jet milling followed by planetary ball milling using polysorbate 80 and mannitol as stabilizers. Formulation was characterized for particle size, PDI, zeta potential, drug assay, surface morphology (TEM, SEM), FTIR, DSC and PXRD. In vitro dissolution was performed at pH 1.2 and pH 7.4. Antiplasmodial IC₅₀ was determined against Plasmodium falciparum-infected red blood cells. In vivo antimalarial efficacy (Peter's four-day suppressive test), pharmacokinetics, tissue distribution and repeateddose toxicity were evaluated in Swiss albino mice infected with P. berghei. Results and Discussion: The developed L NS had a particle size of 367.4 ± 2.01 nm, PDI of 0.25, zeta potential of −26.27 ± 2.06 mV, and an assay of 99.36 ± 1.11%. L NS released 92.46% drug at 24 h following first-order kinetics (R² = 0.932). IC₅₀ against P. falciparum was found as 1.184 ng/mL and 16.5 ng/mL for L S, thus a >13- fold improvement. L NS showed improved parasite suppression, higher plasma and tissue AUC values, and no changes in hematological, biochemical and histopathological parameters, confirming safety.

Conclusion

This developed lumefantrine nanosuspension is a promising, scalable, and safe delivery approach for improved antimalarial activity, with the opportunity for food-independent absorption and decreased dosing frequency.

Zitieren

APA

Naik, K., Khanvilkar, V., Patil, U., Ghuge, A., Jadhav, V., Singh, K., & Rane, M. (2026). Development and Evaluation of Lumefantrine Nanosuspension for Enhanced Antimalarial Efficacy and Bioavailability. International Journal of Drug Delivery Technology, 16(52s). https://doi.org/10.25258/ijddt.16.52s.91

Vancouver

Naik K, Khanvilkar V, Patil U, Ghuge A, Jadhav V, Singh K, et al. Development and Evaluation of Lumefantrine Nanosuspension for Enhanced Antimalarial Efficacy and Bioavailability. International Journal of Drug Delivery Technology. 2026;16(52s). doi:10.25258/ijddt.16.52s.91

BibTeX
@article{Naik2026,
  author = {Naik, Kirti and Khanvilkar, Vineeta and Patil, Udaykumar and Ghuge, Aditya and Jadhav, Vaishali and Singh, K.K. and Rane, Mugdha},
  title = {Development and Evaluation of Lumefantrine Nanosuspension for Enhanced Antimalarial Efficacy and Bioavailability},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {52s},
  doi = {10.25258/ijddt.16.52s.91}
}
Kostenlos starten →